---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134793"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:40:05.392846+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500

## Summary
- Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.
- Over 17,500 prescriptions dispensed launch-to-date (+361% vs last quarterly report); >3,800 prescribers.
- SG&A expenses $62.0M (up from $18.6M YoY) reflecting commercial infrastructure build and marketing.
- Cigna added VOQUEZNA to formularies; commercial coverage now ~48% of U.S. commercial lives (~72M covered).
- FDA PDUFA date July 19, 2024 for NERD indication; Phase 3 NERD and Phase 2 EoE studies planned later in 2024.

## SEC filing metadata
- accession: 0001193125-24-134793
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/0001193125-24-134793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/d837391d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134793
- JSON: https://secwatch.observer/filing/0001193125-24-134793.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134793.txt

## Key facts
- Earnings Releases
  Phathom Pharmaceuticals, Inc. reported the first quarter of 2024 results: revenue Net revenues for the first quarter 2024 were $1.9 million, net income Net loss for the first quarter 2024 was $82.9 million.
  - Period: the first quarter of 2024
  - Revenue: Net revenues for the first quarter 2024 were $1.9 million
  - Net income: Net loss for the first quarter 2024 was $82.9 million
  - Result: reported results
  source text: Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/0001193125-24-134793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.